Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on LinkedIn:
“It’s ASCO 2026 plenary day!
Excited for a packed room to hear the results from Proteus today!
Plenaries are about heralding a significant change in clinical practice. It’s a moment where the cancer community comes together and everything stops to hear the most impactful and important research! It’s about more hope and more time for patients. See you in the plenary room later with the Johnson & Johnson Innovative Medicine team excited to share these new results.”
Other articles featuring Mark Wildgust on OncoDaily.